SCHEMBL3345694

SCHEMBL3345694

CC(C)(C)OC(=O)C=Cc1cccc(Br)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B3 P37058 1/20 0.61
▸ PKM P14618 1/20 0.58
▸ SLC6A19 Q695T7 1/20 0.54
▸ MAOB P27338 2/20 0.50
▸ MAOA P21397 1/20 0.50
▸ BACE1 P56817 1/20 0.50
▸ CYP2D6 P10635 1/20 0.49
▸ CYP1B1 Q16678 1/20 0.49
▸ MEN1 O00255 3/20 0.48
▸ KMT2A Q03164 3/20 0.48
▸ HTT P42858 2/20 0.48
▸ POLB P06746 1/20 0.47
▸ NR1H4 Q96RI1 3/20 0.46
▸ NPC1 O15118 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ RELA Q04206 1/20 0.45
▸ ATM Q13315 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2209337 1.00 HSD17B3 (0.61) HSD17B3PKMSLC6A19MAOBMAOA
SCHEMBL18843946 0.83 MAOA (0.51) MAOBMAOAMEN1KMT2APOLB
SCHEMBL2330043 0.83 NR1H4 (0.47) HSD17B3PKMMEN1KMT2APOLB
SCHEMBL7911109 0.83 NR1H4 (0.47) HSD17B3PKMMEN1KMT2APOLB
SCHEMBL1132527 0.83 HSD17B3 (0.67) HSD17B3PKMSLC6A19MAOBMAOA
SCHEMBL322249 0.83 HSD17B3 (0.67) HSD17B3PKMSLC6A19MAOBMAOA
SCHEMBL30628952 0.82 PTPN1 (0.48) HSD17B3PKMMAOBMAOAMEN1
SCHEMBL26750709 0.82 PTPN1 (0.48) HSD17B3PKMMAOBMAOAMEN1
SCHEMBL7499058 0.82 NPSR1 (0.59) PKMMAOBMAOANR1H4NPC1
SCHEMBL7499052 0.82 NPSR1 (0.59) PKMMAOBMAOANR1H4NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022121844-A1 DIHYDROPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 上海维申医药有限公司 2022-06-16 — — WO disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 — — US disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 — — WO disclosed
EP-1013639-B1 Aryl carboxylic acid and tetrazole derivatives comprising a carbamoyloxy unit HOFFMANN LA ROCHE (CH) 2003-10-01 — — EP disclosed
US-6335459-B1 PROSTAGLANDIN I2 RECEPTOR MODULATORS; TREATING TISSUE NECROSIS, PREMATURE UTERINE CONTRACTION, GASTRIC ULCERATION, SEXUAL DYSFUNCTION, MENSTRUAL PAIN AND IMPROPER WOUND HEALING, IMMUNOREGULATION, PLATELET AGGREGATION OR NEUTROPHIL FUNCTION SYNTEX (U.S.A.) LLC 2002-01-01 — — US disclosed
EP-1013639-A1 Aryl carboxylic acid and tetrazole derivatives comprising a carbamoyloxy unit F. HOFFMANN-LA ROCHE AG (CH) 2000-06-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD HSD17B3 704/4885PKM 1038/4885SLC6A19 2231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback